← All trials
NCT05899179
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 3, 2023
- Primary completion
- Jun 30, 2025
- Completion date
- Oct 31, 2025
- First posted
- Jun 12, 2023
- Last posted
- Aug 22, 2023
- Enrollment
- 780
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.Lead sponsor
- Huazhong University of Science and TechnologyCollaborator
- Shenzhen Third People's HospitalCollaborator
- Shenzhen Third People's HospitalOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.